ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Sees Significant Decrease in Short Interest

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) was the target of a significant decrease in short interest in February. As of February 15th, there was short interest totalling 97,800 shares, a decrease of 24.5% from the January 31st total of 129,600 shares. Based on an average daily trading volume, of 774,100 shares, the days-to-cover ratio is currently 0.1 days. Approximately 4.2% of the shares of the company are sold short.

ZyVersa Therapeutics Stock Down 7.1 %

ZVSA stock opened at $1.05 on Tuesday. The business’s 50-day moving average price is $1.27 and its 200-day moving average price is $1.72. ZyVersa Therapeutics has a twelve month low of $0.98 and a twelve month high of $10.80.

Hedge Funds Weigh In On ZyVersa Therapeutics

An institutional investor recently bought a new position in ZyVersa Therapeutics stock. Virtu Financial LLC bought a new stake in shares of ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 25,259 shares of the company’s stock, valued at approximately $27,000. Virtu Financial LLC owned approximately 1.08% of ZyVersa Therapeutics as of its most recent filing with the Securities and Exchange Commission. 3.91% of the stock is currently owned by hedge funds and other institutional investors.

About ZyVersa Therapeutics

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity.